Curaleaf Laboratories has introduced the launch of the UK’s first CE-certified liquid medical hashish inhaler, aiming to deal with rising affected person and scientific demand for a discreet and dependable inhalation technique.
The Curaleaf Que Medical Inhalation Machine (QMID), designed in partnership with Jupiter Analysis LLC, shall be accessible on prescription to all UK medical hashish clinics.
Its new rechargeable machine makes use of Curaleaf’s already accessible EU-GMP liquid extract cartridges, and has a minimal lifespan of six months from first use, delivering as much as 240 inhalations with a 1.0mL cartridge.
QMID has been purpose-built from the bottom up as a scientific machine, and represents the primary CE-certified machine of its form to hit the UK market.
Which means that the inhaler has handed rigorous European regulatory scrutiny relating to security, reliability and repeatability throughout a number of use circumstances, and is formally deemed a Class IIa machine below the EU Medical Machine Regulation.
Apart from giving each prescribers and sufferers confidence in its therapeutic suitability and regulatory compliance, this give attention to scientific utility signifies that the amount of remedy delivered has been measured utilizing internationally recognised standards, guaranteeing dependable supply throughout all administrations.
Activated upon inhalation, the dearth of buttons or menus means the machine is easy to make use of, discreet and well-suited for each scientific supervision and residential use for eligible sufferers who’re applicable for inhaled hashish medicines.
Jonathan Hodgson, UK Managing Director at Curaleaf Worldwide, commented: “For the primary time, inhaled liquid hashish may be administered with managed precision via a registered handheld machine — giving prescribers and sufferers new confidence in therapy supply.
“Not like unregulated or consumer-grade vaporisers, this machine is purpose-built for scientific use, with standardised supply, medical-grade elements, and compatibility with formulations that meet European Pharmacopoeia requirements.”
READ MORE: Curaleaf Worldwide’s Strategic Strikes in Europe: Unique Insights from Juan Martinez
The inhaler provides to Curaleaf’s present product vary within the UK, which incorporates oils, dried flower, capsules, pastilles, topicals and vaporisation merchandise. The corporate can also be working with regulators in Germany, Poland, Australia and different markets to safe approvals for the brand new machine.
Curaleaf Worldwide continues to collaborate with regulators, healthcare suppliers and pharmacists throughout a number of areas, aiming to develop entry to cannabinoid-based medicines consistent with evolving scientific frameworks.
Juan Martinez, Worldwide CEO at Curaleaf, stated: “The launch of this licensed Curaleaf machine displays the following section of innovation and positions Curaleaf on the forefront of a differentiated, pharma-grade supply platform that addresses rising international demand for precision hashish therapies.
“It’s a part of our wider mission to make medical hashish extra accessible, extra constant, and built-in into mainstream healthcare techniques.”
